Email this article Use of alpha-adrenoblockers intherapy of benign prostatic hyperplasia in patients with arterial hypertension
- Authors: Mazo EВ1, Shashin MN1
-
Affiliations:
- Issue: Vol 79, No 10 (2004)
- Pages: 72-74
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29927
- ID: 29927
Cite item
Full Text
Abstract
Aim. To compare efficacy and tolerance of tonocardin (doxazosin) and omnik (tamsulosin) in the
treatment of benign prostatic hyperplasia (BPH) in hypertensive patients.
Material and methods. Group 1 patients (n = 115, age 44-81 years) with BPH and mild or moderate
arterial hypertension (AH) treated with one antihypertensive drug (ACE inhibitor - 48, calcium antagonist - 26, beta-blocker - 22, diuretic - 19) were given tonocardin in a single daily dose from 1
to 4 mgfor 12 weeks. Group 2 patients (n ~ 30, age 67-81 years) with BPH and severe AH treated
with two antihypertensive drugs and more were given omnik in a single daily dose 0.4 mgfor 12 weeks.
Results. In group 1, tonocardin treatment resulted in lowering of a total symptoms score by IPSS scale
from 17.5 ± 3.6 to 14.7 ± 1.3 points, of quality of life from 4.3 ±0.7 to 3.9 ± 0.3, in a rise of maximal velocity of urine flow (Qmax) from 7.8 ± 1.2 to 9.4 ± 0.6 ml/s; residual urine (R) reduced from
112.4 ± 8.6 to 64.5 ± 10.2 ml). Systolic arterial pressure went down from 150.5 ± 13 to
139.8 ± 13.3 mm Hg, diastolic pressure fell from 86.9 ± 6.1 to 80.8 ± 7.1 mm Hg. In group 2, omnik
resulted in IPSS scale points lowering from 17. 7 ± 3.5 to 15 ± 1.1 , QOL from 4.5 ± 0.2 to
3.8 ± 0.2, Qmax from 7.4 ± 1.1 to 9.2 ± 0.5 ml/s, Rfrom 107.5 ± 12.7 to 63.4 ±9.7 ml. Arterial
pressure did not change much.
Conclusion. Tonocardin and omnik are effective and safe not only in the treatment of BPH but also of
BPH combination with AH.
treatment of benign prostatic hyperplasia (BPH) in hypertensive patients.
Material and methods. Group 1 patients (n = 115, age 44-81 years) with BPH and mild or moderate
arterial hypertension (AH) treated with one antihypertensive drug (ACE inhibitor - 48, calcium antagonist - 26, beta-blocker - 22, diuretic - 19) were given tonocardin in a single daily dose from 1
to 4 mgfor 12 weeks. Group 2 patients (n ~ 30, age 67-81 years) with BPH and severe AH treated
with two antihypertensive drugs and more were given omnik in a single daily dose 0.4 mgfor 12 weeks.
Results. In group 1, tonocardin treatment resulted in lowering of a total symptoms score by IPSS scale
from 17.5 ± 3.6 to 14.7 ± 1.3 points, of quality of life from 4.3 ±0.7 to 3.9 ± 0.3, in a rise of maximal velocity of urine flow (Qmax) from 7.8 ± 1.2 to 9.4 ± 0.6 ml/s; residual urine (R) reduced from
112.4 ± 8.6 to 64.5 ± 10.2 ml). Systolic arterial pressure went down from 150.5 ± 13 to
139.8 ± 13.3 mm Hg, diastolic pressure fell from 86.9 ± 6.1 to 80.8 ± 7.1 mm Hg. In group 2, omnik
resulted in IPSS scale points lowering from 17. 7 ± 3.5 to 15 ± 1.1 , QOL from 4.5 ± 0.2 to
3.8 ± 0.2, Qmax from 7.4 ± 1.1 to 9.2 ± 0.5 ml/s, Rfrom 107.5 ± 12.7 to 63.4 ±9.7 ml. Arterial
pressure did not change much.
Conclusion. Tonocardin and omnik are effective and safe not only in the treatment of BPH but also of
BPH combination with AH.
References
- Мазо Е. Б. Достижения в медикаментозном лечении доброкачественной гиперплазии простаты. В кн.: Материалы Симпозиума "Новый взгляд на патогенез и лечение доброкачественной гиперплазии предстательной железы. Мировой опыт". М.; 2002. 7-10.
- Пушкарь Д. Ю., Лоран О. Б., Раснер П. И. Медикаментозная терапия альфа-адреноблокаторами в урологии. Мед. консилиум 2002; 7. 377-381.
- Сивков А. В., Аполихин О. И. Альфа1-адреноблокаторы в терапии доброкачественной гиперплазии предстательной железы. Мед. консилиум 2002; 7. 381-384.
- Савенков М. П., Иванов С. Н. Роль гемодинамических реакций при выборе альфа 1-адреноблокатора для лечения симптомов доброкачественной гиперплазии предстательной железы. В кн.: Материалы Симпозиума "Новый взгляд на патогенез и лечение доброкачественной гиперплазии предстательной железы. Мировой опыт". М.; 2002. 11-18.
- Сивков А. В., Суриков В. Л., Ивлева А. Я. Сравнительная оценка безопасности применения различных альфа!адреноблокаторов у больных доброкачественной гиперплазией предстательной железы по данным суточного монито рирования артериального давления. В кн.: Материалы Всероссийской конф. "Мужское здоровье". М.; 2003. 91- 92.
- Cain М., Pfau A., Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol., 1976; 48: 255-263.
- Martell N., Lugue M. Doxazosin added to singiedrug therapy in hypertensive patients with benign prostatic hypertrophy. Clin. Hypertens. 2001; 3(4). 218-223.
- Guthrie R. M., Siegel R. L A multicenter; community-based study of Doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia. The hypertension and BPH intervention trial (HABIT). Clin. Ther 1999; (10).
- Kirby R. S. Profile of Doxazosin in the hypertensive men with benign prostatic hyperplasia. Br. J. Clin Pract. 1994; 74 (suppl.): 23-28.
- Dunn Ch. J., Matheson A., Faulds D. M. Tamsulosin. A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19 (2); 135-161.
- Балаболкин М. И., Хасанова Э. Р., Трухина Т. В. и др. Тонокардин в комплексном лечении сахарного диабета, сочетающегося с гипертонией. Тер. арх. 2002; 12: 38-41.
Supplementary files
